US2011250296A1PendingUtilityA1

Reverse vitamin k effect via photodynamic oxidation targeted at vascular endothelium, fibrin and blood platelets

30
Individually held — no corporate assignee on recordPriority: Jul 28, 2008Filed: Jun 23, 2011Published: Oct 13, 2011
Est. expiryJul 28, 2028(~2 yrs left)· nominal 20-yr term from priority
Inventors:David E. Winslow
A61K 31/403A61K 33/34A61P 7/02A61K 33/06A61K 33/32A61K 31/5415A61K 31/409A61K 31/122A61K 9/0019A61K 33/38A61P 9/00A61P 9/10A61K 31/352A61K 33/242
30
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A formulation or preparation for treating and preventing arterial and venous thrombi is provided. This preparation includes a non-metal containing photodynamic dye and a fat soluble vitamin. A method of administration for treatment and prophylaxis of arterial and venous thrombi is also provided. This method includes steps of: combining a non-metal containing photodynamic dye and a fat soluble vitamin; combining the non-metal containing photodynamic dye and fat soluble vitamin with a sodium solution; and administering the combination of non-metal containing photodynamic dye, fat soluble vitamin, and sodium solution as an intravenous drip.

Claims

exact text as granted — not AI-modified
1 . A preparation for treating arterial and venous thrombi comprising:
 a photodynamic dye; and   a fat soluble vitamin.   
     
     
         2 . The preparation of  claim 1 , wherein the photodynamic dye is selected from a group consisting of a benzoporphyrin derivative (BPD) dye, tricarbocyanine dye, tetramethylthionine chloride dye and a xanthene dye. 
     
     
         3 . The preparation of  claim 1 , wherein the fat soluble vitamin is selected from a group consisting of vitamin A and vitamin E. 
     
     
         4 . The preparation of  claim 1 , wherein the photodynamic dye is selected from a group consisting of a verteporfin, methylene blue, indocyanine green and rose bengal. 
     
     
         5 . The preparation of  claim 1 , wherein the non-metal containing photodynamic dye and the fat soluble vitamin are combined with a sodium solution. 
     
     
         6 . The preparation of  claim 1 , wherein the non-metal containing photodynamic dye and the fat soluble vitamin are combined with a sodium chloride solution. 
     
     
         7 . The preparation of  claim 1 , further comprising a metallic additive. 
     
     
         8 . The preparation of  claim 7 , wherein the metallic additive is selected from a group consisting of gold, silver, copper, manganese and magnesium. 
     
     
         9 . The preparation of  claim 1 , further comprising a physiologic carrier solution containing a readily available electron donor compatible with mammalian blood. 
     
     
         10 . A preparation for treating arterial and venous thrombi comprising the following formulation:
 a fat soluble vitamin combined with a first solvent;   a first non-metal containing photodynamic dye combined with the fat soluble vitamin combined with the first solvent;   a second solvent;   wherein a first portion of the second solvent is combined with the first non-metal containing photodynamic dye, fat soluble vitamin, and first solvent;   a second non-metal containing photodynamic dye;   wherein a second portion of the second solvent is combined with the second non-metal containing photodynamic dye, and   wherein the first portion of the second solvent combined with the first non-metal containing photodynamic dye, fat soluble vitamin, and first solvent is combined with the second portion of the second solvent combined with the second non-metal containing photodynamic dye.   
     
     
         11 . The preparation of  claim 10 , wherein the formulation further comprises: the first solvent is about 20 wt % geraniol tetroxane in DMSO; the second solvent is about 99% DMSO; the first non-metal containing photodynamic dye is about 0.0132 wt % verteporfin; and the second non-metal containing photodynamic dye is <5 wt % sodium iodide of IC Green if IC Green is used or 0.0176 wt % sodium iodide if sodium iodide replaces IC Green. 
     
     
         12 . The preparation of  claim 11 , further comprising a third non-metal containing photodynamic dye being about 0.0574 wt % rose bengal. 
     
     
         13 . The preparation of  claim 10 , wherein the first non-metal containing photodynamic dye is verteporfin. 
     
     
         14 . The preparation of  claim 10 , wherein the first solvent comprises dimethyl sulfoxide and carboxylic acid derivatives. 
     
     
         15 . The preparation of  claim 10 , wherein the second solvent comprises DMSO. 
     
     
         16 . The preparation of  claim 10 , wherein the second non-metal containing photodynamic dye is selected from a group consisting of verteporfin, indocyanine green, and methylene blue. 
     
     
         17 . The preparation of  claim 10 , further comprising a sodium solution that is combined with the first portion of the second solvent combined with the first non-metal containing photodynamic dye, fat soluble vitamin, and first solvent combined with the second portion of the second solvent combined with the second non-metal containing photodynamic dye. 
     
     
         18 . The preparation of  claim 11 , further comprising about 0.0132% benzoporphyrin derivative. 
     
     
         19 . The preparation of  claim 11 , further comprising a third solvent of about 2.8236 wt % geraniol tetroxane in DMSO. 
     
     
         20 . A method of administration for treatment and prophylaxis of arterial and venous thrombi comprising:
 a) combining a non-metal containing photodynamic dye and a fat soluble vitamin;   b) combining the non-metal containing photodynamic dye and fat soluble vitamin with a sodium solution; and   c) administering the combination of non-metal containing photodynamic dye, fat soluble vitamin, and sodium solution as an intravenous drip.   
     
     
         21 . The method of  claim 20 , further comprising the step of administering the intravenous drip for about 10 to 60 minutes. 
     
     
         22 . The method of  claim 21 , further comprising the step of repeating the administration of the intravenous drip on a daily basis for up to eight days. 
     
     
         23 . The method of  claim 20 , further comprising the step of combining a non-metal containing photodynamic dye that is selected from a group consisting of a tricarbocyanine dye, tetramethylthionine chloride dye and a xanthene dye. 
     
     
         24 . The method of  claim 20 , further comprising the step of combining the fat soluble vitamin that is selected from a group consisting of vitamin A and vitamin E. 
     
     
         25 . The method of  claim 20 , further comprising the step of combining the photodynamic dye that is selected from a group consisting of a verteporfin, methylene blue and indocyanine green/sodium iodide and rose bengal. 
     
     
         26 . The method of  claim 20 , further comprising the step of combining the non-metal containing photodynamic dye and fat soluble vitamin with the sodium solution that is a sodium chloride solution. 
     
     
         27 . The method of  claim 20 , further comprising the step of combining the non-metal containing photodynamic dye, fat soluble vitamin, sodium solution with a metallic additive. 
     
     
         28 . The method of  claim 20 , further comprising the step of combining the non-metal containing photodynamic dye, fat soluble vitamin, sodium solution with the metallic additive that is selected from a group consisting of gold, silver, copper, manganese and magnesium. 
     
     
         29 . A preparation of treating arterial and venous thrombi comprising:
 about 0.0088 weight percent methylene blue, about 0.0176 weight percent sodium iodide, about 0.0574 weight percent rose bengal, and the balance being an intravenous solution and a fat soluble vitamin.   
     
     
         30 . The preparation of treating arterial and venous thrombi of  claim 29 , wherein the intravenous solution further comprises about 2.8236 weight percent geraniol tetroxane in DMSO, about 97.0617 weight percent DMSO, and about 0.0132 weight percent benzoporphyrin derivative.

Join the waitlist — get patent alerts

Track US2011250296A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.